Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 12;8(9):e20262.
doi: 10.5812/jjm.20262. eCollection 2015 Sep.

Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features

Vahdat Poortahmasebi  1 , Reza Malekzadeh  2 , Ghodratollah Montazeri  2 , Ehsan Fakhari  1 , Mehdi Norouzi  1 , Azam Khamseh  1 , Masoud Mahmoodi Karkhaneh  1 , Ahmad Tavakoli  1 , Seyed Mohammad Jazayeri  1
Affiliations

Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features

Vahdat Poortahmasebi et al. Jundishapur J Microbiol. .

Abstract

Background: Long-term lamivudine therapy, despite its initial effectiveness against hepatitis B virus (HBV), is associated with the emergence of drug resistance mutations in polymerase protein.

Objectives: The aim of the present study was to determine the prevalence of precore and lamivudine drug resistance mutations in lamivudine treated patients with chronic B hepatitis.

Patients and methods: Sequential sera were obtained from 88 chronic HBV carriers who received lamivudine for more than 24 months. Polymerase and precore regions were directly sequenced for these groups: I (before treatment), II, and III (12 and 24 months after treatment, respectively).

Results: All patients (100%) were contained genotype D, subtype ayw2. One (1.1%), 12 (13.6%), and 22 (25%) members of groups I, II, and III had the replacement of either isoleucine or valine instead of methionine in tyrosine-methionine-aspartate-aspartate (YMDD) motif, respectively. The frequency of mutations from 0 time point to 12 and 24 months showed that there was an increasing trend between sequential samples (P < 0.001). In group I, 31 (35.2%); II, 36 (41.0%) and III, 41 (46.6%) members had the precore stop codon mutations. The frequency of mutations from 0 time point to 12 and 24 months showed that there was an ascending trend between sequential samples. Indeed, frequency of precore stop codon was significantly increased with the passage of time (P < 0.001).

Conclusions: Presence of drug resistance mutations among the patients was significant. Precore mutations were common amongst Iranian HBV chronic carriers under lamivudine therapy and these mutations were accompanied by clinical relapse.

Keywords: Lamivudine; Mutations; Therapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Prevalence of YIDD and YVDD (Polymerase) and Precore Mutations Patients at Time: 0, 12, and 24 (Months).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Matsuda K. Novel susceptibility loci for hepatocellular carcinoma in chronic HBV carriers. Hepatobiliary Surg Nutr. 2012;1(1):59–60. doi: 10.3978/j.issn.2304-3881.2012.10.17. - DOI - PMC - PubMed
    1. Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, et al. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012;1(6):174–83. doi: 10.5501/wjv.v1.i6.174. - DOI - PMC - PubMed
    1. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61–8. doi: 10.1056/NEJM199807093390201. - DOI - PubMed
    1. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology. 1997;25(1):241–4. doi: 10.1002/hep.510250144. - DOI - PubMed
    1. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology. 2001;33(4):963–71. doi: 10.1053/jhep.2001.23045. - DOI - PubMed

LinkOut - more resources